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doi:10.1016/j.jtcvs.2007.10.0721036 The Journal of Thoracic and CarObjective: The objective of this study is to establish clinical evidence that the p53
genotype can serve as a predictive marker for response to cisplatin-based induction
therapy.
Methods: Patients with advanced non–small cell lung cancer who had received neo-
adjuvant chemotherapy in the context of a prospective phase II trial were analyzed for
the p53 genotype of their tumors. Response to induction therapy was then correlated
to the p53 genotype as assessed by complete direct DNA sequencing. Patients had re-
ceived 3 cycles of cisplatin and etoposide, and 1 cycle of simultaneous radiochemo-
therapy. All 3 treatment components mediate their cytotoxic effect through induction
of apoptosis, which is suggested to require an intact p53 gene. In addition, the results
from a previously published hypothesis-finding study are updated to demonstrate the
consistency of clinical results and summarize currently available clinical evidence.
Results: In the phase II trial, 35 patients underwent resection after induction chemo-
therapy, allowing a pathohistologic response assessment. The presence of a mutant
p53 genotype was highly indicative of resistance to induction chemotherapy (P ,
.002). The sensitivity of a mutant p53 genotype to identify nonresponders was 94%
(71.3–99.9 confidence interval). A normal p53 gene was significantly associated
with radical resection (P , .004) and survival advantage (P 5 .02).
Conclusion: This is the second clinical evaluation demonstrating a significant relation
between p53 genotype and response to induction therapy in non–small cell lung
cancer. We conclude that the p53 genotype should be evaluated as a predictive marker
for response to induction therapy in prospective randomized protocols.
I
nduction chemotherapy as treatment strategy for advanced stage non–small cell
lung cancer (NSCLC) remains controversial. Despite the advantages of neoadju-
vant chemotherapy (reduction of tumor burden, activity against micrometastases,
patient compliance, response assessment), it is not yet widely accepted as standard
treatment in advanced NSCLC.1 Multiple randomized phase III trials have shown
that the use of inductive cisplatin-based chemotherapy or chemoradiation before sur-
gery can improve survivals up to 30% at 3 years.2-7 In an update of a systematic re-
view, a 12% relative survival benefit equivalent to an absolute improvement in
survival of 5% at 5 years was suggested.8 However, the beneficial effect of neoadju-
vant chemotherapy seems to be restricted to responders only. In a recently published
large randomized trial (MRC LI22/NVALT’’/EORTC 08012), neoadjuvant chemo-
therapy resulted in a good response rate in 49% of patients.8 However the beneficial
effect of neoadjuvant chemotherapy appears to be restricted to responders only. This
implies that approximately 50% of patients with NSCLC currently do not benefit from
standard neoadjuvant therapy. The efficacy of chemotherapy needs to be improved,
and the identification of predictive markers is a promising strategy. Tumor-specificdiovascular Surgery c May 2008
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genetic alterations affecting possible pathways for chemo-
therapy resistance may serve as candidates to individualize
and improve treatment.
The p53 gene is a well-known candidate gene for predict-
ing response to chemotherapy. It is generally accepted that
the cytotoxicity of drugs interacting with DNA is not medi-
ated through DNA damage itself but through induction of
apoptosis. DNA damage is the strongest trigger for the acti-
vation of the p53 gene, which crucially controls the apoptotic
pathway.9-11 Drugs such as cisplatin and ifosfamide, etopo-
side, doxorubicin, cyclophosphamide, and gemcitabine, as
well as radiation treatment, damage the DNA and conse-
quently activate p53. Inactivation of the p53 gene by muta-
tion may affect response to certain chemotherapies.12,13
Because the p53 gene seems to be the most frequent mutated
gene associated with cancer, this hypothesis was addressed
in various studies.14-16 In an attempt to avoid DNA sequenc-
ing, p53 was analyzed by immunohistochemistry (IHC) or
screening techniques in the majority of these studies. The
sensitivity of these methods to detect p53 mutations varies;
consequently, inconsistent findings have been published. In
the meantime, DNA sequencing is accepted as the gold stan-
dard for p53 testing.17 In vitro studies consistently show that
the p53 genotype plays an important role for response to
treatment.14,18 However, clinical results are still rare.
In 1999 we published a small hypothesis-finding study
showing for the first time a strong relationship between the
presence of a normal p53 gene and response to cisplatin/ifos-
famide-based induction chemotherapy in 25 patients with
NSCLC.16 For that study, we retrospectively recruited the pa-
tients at the University of Vienna; therefore, the study gener-
ated level-of-evidence 3b data (retrospective cohort study).*
The aim of the current study was to advance the clinical
evidence level and provide level-of-evidence 2b data by
analyzing a study cohort that had been recruited prospec-
tively. Therefore, patients with advanced NSCLC who had
received neoadjuvant chemotherapy in the context of a pro-
spective phase II trial at the University of Essen, Germany,
were analyzed.19 The induction treatment consisted of
3 cycles of cisplatin and etoposide and 1 cycle of simulta-
neous radiochemotherapy. Because the cytotoxic effect of
all 3 treatment components is based on their induction of
DNA damage, this cohort seemed suitable for testing the
hypothesis.
* Oxford Centre of Evidence-based Medicine levels of Evidence, May 2001:
www.cebm.netThe Journal of ThoraThis study adds clinical evidence to the suggested inter-
action between the p53 genotype and the chemotherapy
response. In addition, our previously published hypothesis-
finding study is updated to demonstrate the consistency of
clinical results and summarize currently available clinical
data because the number of patients is still small.
Materials and Methods
In 1999, Stamatis and coworkers19 reported the results of a prospec-
tive phase II trial that included 56 patients with stage IIIA and IIIB
NSCLC. In this trial, patients received 3 cycles of cisplatin (60 mg/
m2 days 11 7) and etoposide (150 mg/m2 days 3–5), followed by 1
cycle of simultaneous radiochemotherapy (cisplatin 50 mg/m2 days
2 1 9, etoposide 100 mg/m2 days 4–6, thoracic irradiation 45 Gy).
After induction therapy, 35 of 56 patients were surgically resectable.
For the present analysis, tumor material and response data of the 35
surgically resected patients were provided for p53 analysis.
Patient data and genetic material were handled at the p53 re-
search laboratory at the Surgical Research Laboratories of the Med-
ical University of Vienna under the oversight of the university’s
ethics committee. The laboratory is officially certified by the na-
tional ministry of health in performing molecular genetic analyses
of the p53 gene and handling patient data.
Archived paraffin-embedded tumor material from the diagnostic
biopsies of patients who were included in the prospective phase II
trial was sent to our laboratory for p53 sequencing. The sequencing
results were then correlated to the response data provided. As a con-
trol, the provided response data were compared with the data from
the pathohistologic reports.
Response Category
The 4 response evaluation criteria in solid tumors (RECIST cate-
gories)20—complete remission, partial remission, stable disease,
and progressive disease—were grouped in responders (including
complete remission and partial remission) and nonresponders (includ-
ing stable disease and progressive disease) for statistical evaluation.
Statistical Methods
The 2 (grouped) categories of response to induction treatment (re-
sponders, nonresponders) were correlated with the p53 genotype
(mutated or normal).
The data in the various categories were described with frequen-
cies and percentages, and corresponding associations among the
data were tested with chi-square tests. In cases in which only few
data were available, a Fisher exact test was calculated for 23 2 tables
and an exact Pearson test was calculated for 23 3 tables. The diag-
nostic value of the p53 gene with regard to response to induction
treatment was assessed with sensitivity, specificity, and correspond-
ing 2-sided 95% confidence intervals. In cases of 100% sensitivity or
specificity, corresponding 1-sided 95% confidence intervals were
provided. Survival data are graphically described with Kaplan–Me-
ier curves and tested with log-rank test and Wilcoxon tests.21,22 All P
values are 2-sided.
P53 Gene Sequencing
Complete DNA sequencing was carried out to assess the p53 geno-
type and identify mutations in the p53 gene using complete direct
DNA sequencing. Tumor DNA was prepared from sections fromcic and Cardiovascular Surgery c Volume 135, Number 5 1037
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TSTABLE 1. Characteristics of investigated patient cohorts
Hypothesis-finding study Actual study
Cisplatin/ifosfamide Cisplatin/etoposide/radiation Combined evaluation
No. of patients 24 35 59
Mean age (y) 59.3 6 10.7 54.9 6 7.9 56.9 6 9.3
Median follow-up (mo) 43.6 64.7 53.2
No. of p53 mutations 8 (33%) 11 (31%) 19 (32%)
The actual study describes the new patient cohort. The hypothesis-finding study contains updated information on our previously published data.tumor tissues that were obtained in the course of diagnostic biopsies
or surgery. The methods of DNA extraction, polymerase chain reac-
tion amplification of the p53 gene, and purification of the polymer-
ase chain reaction product have been published.16
Sequencing with the ABI Prism 310
Direct sequencing was done using the ABI Prism BigDye Termina-
tor Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems,
Foster City, Calif). Amplification was performed in a total volume
of 10 mL for 25 cycles using 2 mL of purified polymerase chain re-
action product, 2 pmol of primer (sense or antisense), and 2 mL of
Terminator Ready Reaction Mix. For T1 Thermocycler (Biometra,
Go¨ttingen, Germany), the following thermal profiles were used:
10-second denaturation at 96C, 5-second annealing at 50C, and
4-minute extension at 60C. Sequence reaction was then purified
by Centri Sep spin columns (Princeton Separations P/N CS-901,
Adelphia, NJ). Sequence analysis was performed with the ABI
Prism 310 Genetic Analyzer (PE Applied Biosystems).
Results
Patient Characteristics
Patient characteristics are shown in Table 1. Patients of the
actual prospective study differed from patients of the hypoth-
esis-finding study in that the proportion of squamous cell car-
cinoma was higher (74% vs 50%). No significant association
between histologic type and p53 mutation could be found
(Table 2). The proportion of patients with more advanced
disease (stage IIIB) was higher in the actual study cohort
compared with the hypothesis-finding study cohort. The1038 The Journal of Thoracic and Cardiovascular Surgery c Msummarized analysis of the 59 patients reveals that mutations
in the p53 gene are more frequently present in the advanced
stage (IIIB) (Table 2), which is consistent with the literature
(International Agency for Research on Cancer database).
Predicting the Response to Induction Treatment
We identified a strong correlation between patients with
a normal p53 gene and an effective response to cisplatin-
based induction treatment in both studies (Table 3). A mutant
p53 genotype was highly indicative of resistance to the in-
duction treatment regimens used in the 2 studies (cisplatin/
ifosfamide in the hypothesis-finding study and cisplatin/
etoposide/radiation in the actual study).
The sensitivity of predicting response to treatment by p53
status was as high as 94% in the actual study compared with
100% in the hypothesis-finding study and 97% when both
studies were considered together. A normal p53 gene was
significantly associated with radical resection in both studies
(Table 3).
Overall Patient Survival
Patients with a normal p53 gene had a significant survival
advantage over patients with mutated p53 (Figure 1).
Characterization of p53 Mutation
Table 4 characterizes the p53 mutations found in the actual
study: Three mutations (numbers 864, 874, and 875) were
found to result in the formation of a STOP codon (representingTABLE 2. Association of clinicopathologic variables and p53 genotype
Hypothesis-finding study Actual study Combined evaluation
p53 mutation
No Yes P No Yes P No Yes P
Histologic type
Adeno 7 4 7 1 14 5
Squamous 8 4 16 10 24 14
Large cell 1 0 NS 1 0 NS 2 0 NS
Stage
IIIA 11 5 18 4 31 10
IIIB 5 3 NS 6 7 .057 9 9 .053
NS, Not significant.ay 2008
Kandioler et al General Thoracic SurgeryTABLE 3. P53 genotype in relation to response to neoadjuvant therapy and radical resection
Hypothesis-finding study Actual study Combined evaluation
p53 normal p53 mutant P value p53 normal p53 mutant P value p53 normal p53 mutant P value
Pathologic response
Responder 16 (100%) 0 16 (94%) 1 (6%) 32 (97%) 1 (3%)
Nonresponder 0 8 (100%) ,.001 8 (44%) 10 (56%) .002 8 (31%) 18 (69%) ,.001
16 8 24 11 40 19
Sensitivity 100% (16/16) CI: 82.9–100 94% (16/17) CI: 71.3 – 99.9 97% (32/33) CI: 84.3–99.9
Specificity 100% (8/8) CI: 68.7–100 56% (10/18) CI: 30.7 – 78.5 69% (18/26) CI: 48.2–85.7
Radical resection
Yes 16 (100%) 4 (50%) 17 (90%) 2 (10%) 33 (85%) 6 (15%)
No 0 4 (50%) .007 7 (44%) 9 (56%) .004 7 (35%) 13 (65%) ,.001
16 8 24 11 40 19
CI, Confidence interval.G
TS2 frameshifts and 1 nonsense mutation), which is deleterious
for the biologic activity of the p53 gene.
One mutant was found to be a silent mutation (number
842), which does not alter the amino acid sequence of the en-
coded protein. Therefore, the affected patient was considered
as ‘‘p53 normal’’ for our analyses.
Discussion
The present publication clinically demonstrates a significant
relation between the p53 genotype and the response to induc-
tion therapy. In this study, the ‘‘p53 genotype’’ is analyzed by
complete DNA sequencing and shows consistent predictive
power compared with our previously published hypothesis-
finding study. Both studies suggest that the p53 genotype
could serve as a predictive marker for a patient’s response
to cisplatin-based induction therapy in advanced NSCLC.
P53 Analysis Method
The impact of the p53 gene on the response to chemotherapy
has been addressed in vitro and in some clinical trials. How-
ever, because of conflicting results obtained in previous stud-
ies, p53 has not been considered a useful predictive marker in
NSCLC.23
Several factors account for the conflicting results. First,
a wide range of techniques have been used for p53 analysis
to avoid complete direct sequencing of the whole gene. Dif-
ferent electrophoresis-based screening techniques have been
applied in selecting patients to be sequenced. Additional se-
quencing, if applied, was often restricted to parts of the gene
(exons 5–8). Therefore, the mutation frequency is likely to be
underreported in such studies.
The use of p53 IHC is based on the observation that mis-
sense mutations alter the protein structure, inhibiting rapid
degradation of the protein. Therefore, accumulation of p53
protein was suggested to indicate the presence of p53 gene
mutations. Different antibodies and cutoffs were used to de-
termine a tumor as p53-accumulation positive. Apart from
this lack of standardization, the sensitivity and specificityThe Journal of Thorof IHC are affected by false-positive and false-negative
IHC results: Accumulation of the p53 protein can occur as
a result of physiologic stabilization or overexpression result-
ing from genotoxic stress. Because most antibodies are not
able to discriminate between wild-type and mutant p53 pro-
tein, this will result in false-positive IHC. Complete absence
of p53 protein can be caused by deleterious gene mutations.
The latter prevent the transcription of the gene and result in
false-negative IHC results.24
Because of the inherent bias concerning the analytic tech-
niques that have been used, the results of existing studies as-
sessing the predictive value of p53 are of limited value. In our
recent review of the literature on the predictive value of p53
in the treatment of breast cancer, response to treatment seems
to be consistent and linked to the p53 sequencing results but
not to IHC.17
Complete direct sequencing of the entire p53 gene (exons
2–11) is currently the most reliable, standardized, and sensi-
tive method to evaluate p53 gene mutations.
Chemotherapy Resistance in NSCLC
d’Amato and colleagues25 recently published preclinical data
on the resistance of NSCLC tumor cell cultures to several
chemotherapy agents. They found that tumor cells were fre-
quently resistant to at least 1 agent in chemotherapy doublet
regimens and expressed a possible association between drug
resistance and p53 overexpression. They observed that many
tumors exhibit simultaneous resistance to platinum agents
and gemcitabine. Because both drugs act via induction of
DNA damage, these findings support the hypothesis that
functional p53 is required to induce apoptosis as a result of
DNA damage. The reported resistance rates of 60% to 80%
can be explained by the high p53 mutation rates frequently
observed in cell cultures.26
Conclusions
We provide clinical evidence that a normal p53 genotype can
identify patients with NSCLC who will benefit from standardacic and Cardiovascular Surgery c Volume 135, Number 5 1039
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TSFigure 1. Survival benefit after neoadjuvant therapy is related to
a normal p53 genotype in both clinical evaluations, A, Four-year
update of the retrospective, hypothesis finding study; B, Prespec-
tive, actual study; C, Combined calculation of 59 patients.1040 The Journal of Thoracic and Cardiovascular Surgery c Mcisplatin-based induction treatment. We demonstrate that
the presence of a normal p53 gene results in response to in-
duction therapy. In the group of responders, we observed
a high rate of radical resections and prolonged overall sur-
vival.
On the basis of the consistent results of our clinical anal-
yses, we conclude that the p53 genotype should be evalu-
ated as a predictive marker in randomized, neoadjuvant
protocols for NSCLC. Upcoming protocols should consider
the technical aspects of p53 analysis and allow correct
response assessment.
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